Norris Medicines Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is 36.99% vs -46.32% in Jun 2025

Standalone Net Profit

QoQ Growth in quarter ended Sep 2025 is -132.26% vs -34.78% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -390.00% vs -242.86% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is 0.00% vs -26.67% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of Norris Medicines With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

2.00

0.00

2.00

Other Operating Income

0.00

Total Operating income

2.00

0.00

2.00

Raw Material Cost

2.48

0.00

2.48

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

-0.76

0.00

-0.76

Employee Cost

0.44

0.35

0.09

25.71%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

0.33

0.10

0.23

230.00%

Total Expenditure (Excl Depreciation)

2.49

0.45

2.04

453.33%

Operating Profit (PBDIT) excl Other Income

-0.49

-0.45

-0.04

-8.89%

Other Income

0.00

0.03

-0.03

-100.00%

Operating Profit (PBDIT)

-0.49

-0.42

-0.07

-16.67%

Interest

0.11

0.00

0.11

Exceptional Items

0.00

Gross Profit (PBDT)

-0.60

-0.42

-0.18

-42.86%

Depreciation

0.12

0.03

0.09

300.00%

Profit Before Tax

-0.72

-0.45

-0.27

-60.00%

Tax

0.00

Provisions and contingencies

0.00

Profit After Tax

-0.72

-0.45

-0.27

-60.00%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-0.72

-0.45

-0.27

-60.00%

Equity Capital

9.93

11.27

-1.34

-11.89%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

-0.73

-0.40

-0.33

-82.50%

Diluted Earnings per share

-0.72

-0.40

-0.32

-80.00%

Operating Profit Margin (Excl OI)

-24.50%

0.00%

0.00

-24.50%

Gross Profit Margin

-30.00%

0.00%

0.00

-30.00%

PAT Margin

-36.00%

0.00%

0.00

-36.00%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 2.00 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 36.99% vs -46.32% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 57.48% vs -50.39% in Sep 2024

Quarterly - Standalone Net Profit

Standalone Net Profit -0.72 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is -132.26% vs -34.78% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -100.00% vs 25.00% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) -0.49 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is -390.00% vs -242.86% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -226.67% vs 40.00% in Sep 2024

Quarterly - Interest

Interest 0.11 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 0.00% vs -26.67% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 37.50% vs -11.11% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -24.50%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024